Hematologic Cancer News and Features

Earlier and Later Adult BMI Associated With Multiple Myeloma Risk

Earlier and Later Adult BMI Associated With Multiple Myeloma Risk

Younger and usual adult body mass index (BMI) may be linked to increased risk for developing multiple myeloma, research indicates.

Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen

Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen

Pediatric patients and their parents tend to overestimate adherence to anticancer medicine regimen.

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

Patients who were surveyed reported that the benefits of treatment with BV outweighed its risks.

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

PD-1 blockade with pembrolizumab was active and induced durable responses in patients with natural killer (NK)/T-cell lymphoma failing L-asparaginase.

BBD Regimen Efficacious as First-line Therapy for Myeloma

BBD Regimen Efficacious as First-line Therapy for Myeloma

Bendamustine, bortezomib, and dexamethasone is efficacious and tolerable as first-line therapy for patients with myeloma ineligible to receive high-dose therapy.

Allogeneic HCT Effective in Older Patients with AML in Second Complete Remission

Allogeneic HCT Effective in Older Patients with AML in Second Complete Remission

Researchers determined the curative potential of allogenic hematopoetic stem cell transplantation in patients aged 60 years and older with acute myeloid leukemia in second complete remission.

Two Infants Achieve Leukemia Remission After Gene Therapy

Two Infants Achieve Leukemia Remission After Gene Therapy

Two infants with advanced acute lymphoblastic leukemia (ALL) achieved full remission following gene therapy involving modified autologous CAR-T cells.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs